VYVGART PDUFA May 10; Intellia CRISPR shows gains

argenx VYVGART (efgartigimod) for seronegative generalized myasthenia hits May 10 PDUFA. Intellia's lonvo-z for hereditary angioedema showed 87% attack-rate cut vs. placebo in phase 3, with 60% remaining attack-free (vs. 11% placebo), signaling the first in vivo CRISPR path to approval.